Do you think LE may have changed his buyout target numbers since mentioning 5-10B?  I look at Pharmasatt getting what they did for a Hepatitis C drug, the revenue that the top 2 psoriasis drugs brought in in 2012 and I expect Prurisol to eat them for lunch, the potential yearly revenue from Kevetrin should it prove effective,etc. and it looks like $5-10B would be a steal for CTIX, especially looking at the pipeline of drugs in waiting and the unknown as of yet number of combinations they would both expect to come to be in the next few years.